Drug news

Giotrif fails two Phase III trials for Breast Cancer- Boehringer

Read time: 1 mins

Last updated:17th Dec 2014

Published:17th Dec 2014

Source: Pharmawand

In the Phase III LUX-BREAST 1 study Giotrif (afatinib) plus vinorelbine (The Boehringer combination) showed a similar progression free survival and objective response rate and shorter overall survival compared to Herceptin (trastuzumab) and vinorelbine in HER-2 positive metastatic Breast Cancer patients after failure of prior Herceptin therapy.The Boehringer combination was less well tolerated with higher rates of treatment discontinuation.

In the Phase III LUX-BREAST 3 study in HER 2 positive Breast Cancer progressing with Brain Cancer metastases the Giotrif, Boehringer combination data after prior trastuzumab and/or lapatinib ( Tyver/Tykerb) based therapy showed no benefit for Giotrif or the Boehringer combination over investigators choice as measured by patient benefit at 12 weeks,progression free survival or overall survival.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Safety of switching from a Vitamin K antagonist to a non–Vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation.

FRAIL-AF trial investigators set out to study the question of whether frail, elderly patients with atrial fibrillation who were doing well with vitamin K antagonists (VKA) should be switched to direct-acting oral anticoagulants (DOAC).

1 mins

Drug news

FDA approves updated Lupkynis (voclosporin) label to include long term data from the Aurora Clinical Program.-- Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals Inc. announced that the FDA has approved a label update for Lupkynis. The updated label no longer includes language indicating that the safety and efficacy of Lupkynis has not been established beyond one year.

3 min

Drug news

Phase III KEYNOTE-811 trial met dual primary endpoint of overall survival (OS) as first-line treatment in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.- Merck Inc.,

Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival (OS) for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

1 min

See all news